Écrit par WHO			
				
			|	
						
				03 Juin 2013			
			
				
		
				
				
		
 02/06/2013 - The  Ministry of Health in Italy, through the European Union’s Early Warning  Response System has notified WHO of an additional two  laboratory-confirmed cases with Middle East respiratory syndrome  coronavirus (MERS-CoV) in the country.
02/06/2013 - The  Ministry of Health in Italy, through the European Union’s Early Warning  Response System has notified WHO of an additional two  laboratory-confirmed cases with Middle East respiratory syndrome  coronavirus (MERS-CoV) in the country. 
 
 Both  the patients are close contacts of the recent laboratory-confirmed case  with recent travel from Jordan. The first patient is a two-year-old  girl and the second patient is a 42-year-old woman. They are in stable  condition. 
 
 Globally,  from September 2012 to date, WHO has been informed of a total of 53  laboratory-confirmed cases of infection with MERS-CoV, including 30  deaths. 
 
 WHO  has received reports of laboratory-confirmed cases originating in the  following countries in the Middle East to date: Jordan, Qatar, Saudi  Arabia, and the United Arab Emirates (UAE). France, Germany,  Italy,Tunisia and the United Kingdom also reported laboratory-confirmed  cases; they were either transferred there for care of the disease or  returned from the Middle East and subsequently became ill. In France,  Italy, Tunisia and the United Kingdom, there has been limited local  transmission among patients who had not been to the Middle East but had  been in close contact with the laboratory-confirmed or probable cases. 
 
 Based  on the current situation and available information, WHO encourages all  Member States to continue their surveillance for severe acute  respiratory infections (SARI) and to carefully review any unusual  patterns. 
 
 Health  care providers are advised to maintain vigilance. Recent travellers  returning from the Middle East who develop SARI should be tested for  MERS-CoV as advised in the current surveillance recommendations.  Specimens from patients’ lower respiratory tracts should be obtained for  diagnosis where possible. Clinicians are reminded that MERS-CoV  infection should be considered even with atypical signs and symptoms,  such as diarrhoea, in patients who are immunocompromised. 
 
 Health  care facilities are reminded of the importance of systematic  implementation of infection prevention and control (IPC). Health care  facilities that provide care for patients suspected or confirmed with  MERS-CoV infection should take appropriate measures to decrease the risk  of transmission of the virus to other patients, health care workers and  visitors. 
 
 All  Member States are reminded to promptly assess and notify WHO of any new  case of infection with MERS-CoV, along with information about potential  exposures that may have resulted in infection and a description of the  clinical course. Investigation into the source of exposure should  promptly be initiated to identify the mode of exposure, so that further  transmission of the virus can be prevented. 
 
 WHO  does not advise special screening at points of entry with regard to  this event nor does it currently recommend the application of any travel  or trade restrictions. 
 
 WHO continues to closely monitor the situation.